alerted, strange the nasdaq site is missing this:

"Sophiris Bio Inc :Empery Asset Management Lp reports 8.58 percent passive stake in Sophiris Bio Inc, as of May 6, 2016 - SEC filing."
source:
Reuters, Tuesday, 24 May 2016

The SEC filing on that buy:
SEC filing

Instituational Ownership according Wall Street Journal:
WSJ SPHS company-people

Number of Inst Own according finviz: 20.9 %
finviz.com SPHS

Number of Inst Own according gurufocus: 23.67%
gurufocus SPHS

Bloomberg about Ryan Lane, head of Empery Asset Management Lp:
"Mr. Ryan Matthew Lane is a Managing Partner and Chief Compliance Officer at Empery Asset Management, LP. Previously he was a Co-Founder and Managing Director at Lane Capital Markets, LLC and was a Partner of Investment Banking. He co-founded the firm in 2003 and his knowledge is deep in the health care industry including, due diligence, business planning, in licensing, out licensing and strategic advisory work. To date Mr. Lane has focused his work in the medical technology, ..."

all told not too bad for SPHS
GLTA

agree with you in tendency though a little too pessimistic.

Inst. ownership is over 20 %, maybe you mixed it up with insiders?

Sold EXEL @ $5.05 yesterday -- looking to re-enter

An oncologists table on OncLive about the role of cabozantinib and lenvatinib in RCC Cancer.
(Part nine of discussing treatment options in renal cell carcinoma)

OncLive

Lowest short volume since last july and increasing share volume halved days to cover to 7.4 days in mid march:

http://www.nasdaq.com/symbol/exel/short-interest

right with all these good news over the last months pps for EXEL is absolutely ridiculous.

Today comes another good news, approval of Cotellic in combi with Zelboraf for melanoma in Canada.

newswire.ca

The closer we come to US and EU approval of Cometriq for RCC we hopefully see a rising share prize here. Perhaps one sunny April afternoon...

See all slides of the Exelixis-Ipson Deal:

>>>> pdf slides Exelixis <<<<

Exelixis and Ipsen Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Regions Outside the United States, Canada and Japan

- Cabozantinib commercialized for medullary thyroid cancer (MTC) and filed for advanced renal cell carcinoma (RCC) -

- $200 million upfront payment and subsequent regulatory and commercial milestones -

press release by Exelixis

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb. 15, 2016-- Exelixis, Inc. (NASDAQ:EXEL) announced today that its fourth quarter and full year 2015 financial results will be released on Monday, February 29, 2016 after the markets close. At 5:00 p.m. EST / 2:00 p.m. PST, Exelixis management will host a conference call to discuss the results and provide a general business update. The conference call will be accessible via the Internet from the company’s website.

exelixis press releases

"Exelixis is looking at a de-risked revenue stream of $850M per year"

Buying more Exelixis following positive renal cancer data

Ohad Hammer's look at Exelixis:

Ohad Hammer Blog

could mean short attack tomorrow morning eom

nanamina, yes will be interesting to see ARIA's short volume report this afternoon on nasdaq.
Your shortanalytics link shows high short volume and price went up with it. Strange isn't it?
Found an interesting post written bei Ihub poster slojab about that phenomenon:
An explanation of Finra's daily short volume
Therefore expect much lower sv after 4pm ;)

Joey thanks for your well-elaborated posts, agree with you.

One thing, you wrote
Perhaps 13 million got sold above $.10 cents and they've all sold their 100 million limitations below $.10...
the difference in number of O/S could be a result of the 10% of warrants holders not been undersigning the agreement.

GLTY

i saved my kids from scientology, know what I'm talking about. Change that picture please, there are millions better out there ;)
And thanks for your brillant letters. You are THE great ARIA shareholder, man!

Your new picture really bums me out, man! I guess you ment 'I want the truth' more than the scientology guy transporting these words!

Your letter adressed to Ariad board is great work. Thank you very much. Few here were able to do so.

Think you're right. Realistic. But love 2da's efforts though

realistically, ariad the company will not answer any legitimate question, that reflects the companies future finances and intentions honestly.

Everybody knows now that Southwestern in deed had that 'expect...' sentence on their site and that it was no fake.
But as they removed it yesterday it should not be posted here any longer too.
That's why i deleted it from my picture host's server.
Hope that's OK for everybody here.

Really?
Thanks!

Commenting on the compound, Dr. Richard Sachse, the Company's Chief Medical and Chief Scientific Officer, stated, “We believe that zoptarelin doxorubicin has the potential to become the first FDA approved medical therapy for advanced, recurrent endometrial cancer. This could result in its rapid adoption as a novel core therapy for treatment and management of advanced, recurrent endometrial cancer. Our hope is that the compound will improve and extend the quality of the lives of patients with this devastating disease.”
AEZS news 08-11-2015
'Expect' sounds more concrete than 'believe', 'could' and 'hope', doesn't it?
So as I said in one of my last posts the sentence 'expect...' gives a line of possibly succeccful working with Zopta-Doxo at Southwestern. Barely enough to talk about successful interim results of the trial as a whole.
Just posted picture needed for discussion here. Personally I agree with you 'expect...' not to be that great leaked info :D but nevertheless a puzzle to the whole picture we have to build together.

Didn't understand this:
Plus what about the CRL from earlier this year? That was supposed to be the next newest and best thing ever.
What you mean?

Karin
adding 'source?nasdaq' to the link adress should show you the whole text. If not install QuickJS add-on to your Firefox, then turning of javascript and refreshing site will show whole text for sure ;)
add-on QuickJS for Firefox

maybe, everybody could have done, it's not even amateur hacker's effort

AEZS hard to believe in a successful completion of ZoptEC after all these years they never did succeed in almost anything. I wish they will...

Meanwhile it's pure gambling here...

GLTY





See number 40 MM?

:D
no foresight - just followed the google cache link

disappointed and membermark gone? :D
Thanks!

Possibly UT Southwestern is not allowed to post such an estimation about ZoptEC, so they better removed the statement away from their site.
But it seems to me Zoptarelin-Doxorubicin could have worked fine for Southwestern patients while treating their patients during the study.

Thanks for the membermark
an GLTY with AEZS

Try this Karin, it's the webcache link ;)

webcache link

If needed i've got the screenshot

missed the discussion here?
There are less than 2% short sellers or about 4 mill. shares short here, that's almost none compared to o/s.

unbelievable! Sounds great!
But let me calculate...
50% plus from let's say 0,03.. ok 0,045.. Great!

exactly.
thanks for explaining.

like your effort juggling with apples and oranges lol

there are no shorties here - 2%

yes last chance at this price lol

because Monday you'll get shares much cheaper lol

Everybody have a look which points of breaking the CODE OF ETHICAL CONDUCT fullfilled in the meantime - make your own choice!



ethicspoint.com

4,310,071 compared to O/S 237.7 million is plenty?

Ridiculous

Almost NO short sellers here

Exactly! If Cramer says buy he actually sends the signal to short a stock

Yes, we are listening

Gap is closed
may go up now

Thank you trademan for giving this to the board, great work!

GLTY

TwoPack

That's how red candles start the day usally.